Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
66.76
+0.60 (+0.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
December 12, 2023
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
December 11, 2023
Via
Benzinga
Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions
December 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion...
Via
Benzinga
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
A Look Into Gilead Sciences Inc's Price Over Earnings
December 07, 2023
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
December 06, 2023
Via
Benzinga
Looking Into Gilead Sciences's Recent Short Interest
November 22, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
November 21, 2023
Via
Benzinga
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
December 07, 2023
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via
InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
Via
InvestorPlace
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Via
The Motley Fool
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
November 26, 2023
There's no time like the present to buy these stocks.
Via
The Motley Fool
Is NASDAQ:GILD suited for dividend investing?
November 20, 2023
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD).
Via
Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
November 15, 2023
Via
Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
November 09, 2023
Via
Benzinga
Stocks Stall On November 21, 2023, As Systematic Flows Abate
November 21, 2023
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied
Via
Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...
Via
Benzinga
Exposures
Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
November 17, 2023
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying.
Via
Chartmill
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
November 15, 2023
The companies will work together on treatments for multiple myeloma and lymphomas.
Via
Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
Where Gilead Sciences Stands With Analysts
November 09, 2023
Via
Benzinga
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
November 07, 2023
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
Via
Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
November 07, 2023
GILD earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
November 07, 2023
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's
Via
Benzinga
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs
November 07, 2023
The biotech company makes three notable treatments for cancer.
Via
Investor's Business Daily
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
November 07, 2023
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month...
Via
Benzinga
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
November 07, 2023
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today
November 06, 2023
Via
Benzinga
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
November 03, 2023
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...
Via
Benzinga
Topics
Bonds
Economy
Exposures
Debt Markets
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.